Crown Laboratories
Crown Laboratories, now operating as Revance, is a privately held specialty pharmaceutical and aesthetics company that develops and commercializes FDA-cleared medical devices, injectables, prescription dermatology, and consumer skincare brands across more than 60 countries.
- Company typePrivate
- Founded2000
- HeadquartersJohnson City, United States
- Headcount251–500
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Crown Laboratories does
Crown Laboratories, founded in 2000 and headquartered in Johnson City, Tennessee, is a privately held specialty pharmaceutical company that develops, manufactures, and commercializes dermatology, aesthetics, and consumer skincare products across three operating segments: Aesthetics (SkinPen and MicroPen EVO microneedling devices, ProGen PRP Eclipse platelet-rich plasma systems, DAXXIFY neuromodulator, and Teoxane RHA Collection dermal fillers sold to medical practices), Consumer Skincare (StriVectin, PanOxyl, Blue Lizard Australian Sunscreen, BIOJUVE, Sarna, Keri, Zeasorb, and Desenex sold through mass-market retail and e-commerce), and Prescription dermatology products (Triderm, ALA-CORT, Nystatin) sold through pharmacies, with a complementary CDMO services offering.
The company's underlying technology rests on a portfolio of proprietary platforms including NIA-114 (a patented optimized niacin/vitamin B3 used across all StriVectin formulas), Xycrobe living microbe technology built on Cutibacterium acnes defendens strain XYCM42 (the basis for the BIOJUVE skin biome franchise), ActiSine active retraction technology in the SkinPen Precision Elite, and the peptide-formulated DAXXIFY neurotoxin. Manufacturing is anchored in a 250,000 sq ft FDA-certified, cGMP-compliant facility in Johnson City, TN, which also serves third-party CDMO customers. Distribution spans 60 countries through a combination of a direct aesthetics field sales force, major retail and e-commerce channels (Amazon, Target, Walmart, drugstores), and exclusive U.S. distribution rights for Teoxane.
Following its 2017 acquisition by Hildred Capital Partners and a programmatic series of acquisitions (Bellus Medical, Xycrobe Therapeutics, StriVectin, Eclipse MedCorp, Healeon, and Revance Therapeutics), the company employs more than 750 people across Johnson City, Dallas, and New York. The February 2025 close of the $924 million Revance Therapeutics acquisition and subsequent March 2025 rebranding to operate under the Revance name transformed the business into a multi-brand, multi-channel aesthetics and skincare platform with reported 91% three-year revenue growth (2021-2024) and a 12th Inc. 5000 appearance in 2025.
Crown Laboratories firmographics
Firmographics- Name
- Crown Laboratories
- Legal name
- Crown Laboratories, Inc.
- Website
- https://crownlaboratories.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Crown Laboratories, now operating as Revance, is a privately held specialty pharmaceutical and aesthetics company that develops and commercializes FDA-cleared medical devices, injectables, prescription dermatology, and consumer skincare brands across more than 60 countries.
- Ownership category
- akta.pro rank
Crown Laboratories industry classification
Industry- Product category
- Dermatology and Aesthetics Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Health and Personal Care Retailers (456)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where Crown Laboratories is headquartered
LocationHeadquarters
- HQ city
- Johnson City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Crown Laboratories business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Aesthetics Products: Sales of SkinPen microneedling devices, ProGen PRP systems, and related aesthetic medical devices to practitioners. Also includes DAXXIFY neurotoxin and RHA dermal fillers following the Revance acquisition.
- Consumer Skincare Products: Sales of consumer skincare brands including StriVectin, PanOxyl, Blue Lizard, Sarna, Keri, Zeasorb, Desenex, and BIOJUVE through retail and e-commerce channels.
- Prescription and Therapeutic Products: Sales of prescription dermatology products including Triderm, ALA-CORT, Nystatin Cream, and generic products to healthcare providers and patients.
- Contract Development and Manufacturing Services: CDMO services provided to third parties through Crown's 250,000 sq ft FDA-certified, cGMP-compliant facility in Johnson City, TN. Supports development and manufacturing of liquid and semi-solid products.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
Crown Laboratories product offering
Product offeringCore offering
Crown Laboratories is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes aesthetics medical devices, neuromodulator injectables, dermal fillers, prescription dermatology products, and consumer skincare brands. The company sells aesthetics products (SkinPen, DAXXIFY, ProGen PRP, Teoxane RHA fillers) directly to medical practices while distributing consumer skincare brands (StriVectin, PanOxyl, Blue Lizard, BIOJUVE, Sarna, Keri) through retail, e-commerce, and direct-to-consumer channels across 60 countries.
Product overview
Crown Laboratories operates as a diversified pharmaceutical and consumer skincare company with three main business segments: Aesthetics (medical devices and injectable products), Consumer Skincare (OTC and prescription dermatology brands), and Contract Development & Manufacturing (CDMO) services. The aesthetics portfolio includes FDA-cleared microneedling devices (SkinPen, MicroPen EVO), platelet-rich plasma systems (ProGen PRP), the neuromodulator DAXXIFY, and Teoxane RHA dermal fillers. The consumer skincare segment encompasses well-known brands like StriVectin (anti-aging), PanOxyl (acne), Blue Lizard (sunscreen), Sarna (itch relief), and various antifungal products. The company also offers prescription dermatology products and CDMO manufacturing services.
Differentiator
Problem solved
Functional benefit
Brands
- StriVectin: Premium skincare brand powered by patented NIA-114 technology for aging and changing skin
- PanOxyl
- Blue Lizard Australian Sunscreen
- Sarna
- Keri
- Zeasorb
- Desenex
- BIOJUVE
- SkinPen
- ProGen PRP Eclipse
- DAXXIFY
- Teoxane RHA Collection
Products and services
- SkinPen
- SkinPen Precision Elite
- ProGen PRP Eclipse
- DAXXIFY
- Teoxane RHA Collection
- StriVectin
- PanOxyl
- Blue Lizard Australian Sunscreen
- BIOJUVE
- Sarna
- Sarna Eczema Relief Skin Protectant Lotion
- Keri
- Zeasorb
- Desenex
- Blue Lizard After Sun Soothing Lotion
- Triderm
- ALA-CORT
- Nystatin Cream
- Hydrocortisone Cream USP
- Contract Development and Manufacturing (CDMO) Services
Quantifiable outcome
- SkinPen is the first FDA-cleared microneedling device and the number one microneedling brand in the United States
- +4 more outcomes
Companies that use Crown Laboratories
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Crown Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Crown Laboratories partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, minor and core.
- Revance TherapeuticsflagshipCrown Laboratories merged with and acquired Revance Therapeutics in February 2025 for approximately $924 million. The acquisition brought DAXXIFY neurotoxin, RHA dermal fillers, and additional aesthetics capabilities. The combined company now operates under the Revance name.
- Healeon LLC (Bimini Health Tech)minorCrown acquired select assets from Healeon LLC, a subsidiary of Bimini Health Tech, a global leader in innovative medical devices. Details of specific products acquired not specified.
- Teoxane SAcoreRevance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. RHA technology is proprietary to and manufactured in Switzerland by Teoxane SA. The partnership was expanded in 2025 with launch of RHA Collection with Mepivacaine.
- StriVectinflagshipCrown acquired StriVectin, a leading independent prestige skincare brand in the U.S., integrating it into Crown's Premium Skincare Division. StriVectin brings patented NIA-114 technology and over 35 years of clinical research.
- East Tennessee State University (ETSU)minorCrown launched the CLERI (Crown Laboratories Educational Research Initiative) program in collaboration with ETSU exploring changes to skin microbiome treatment. Dr. Thomas Hitchcock and Dr. Mun Su Rhee appointed as adjunct faculty at ETSU Department of Biomedical Sciences.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
Crown Laboratories competitors and assessment
Company assessmentDirect peers
- Galderma: Galderma is a global dermatology-focused company with leading aesthetics franchises (Restylane fillers, Sculptra biostimulator, Dysport neurotoxin) and consumer/therapeutic skincare. It is the most direct competitor to Revance's combined aesthetics + dermatology platform and a benchmark for PE-backed dermatology exits (Galderma IPO'd in 2024).
- Merz Aesthetics: Merz Aesthetics markets Xeomin (neurotoxin), Belotero (HA filler), Radiesse (biostimulator), and Ultherapy (energy device). It is a direct peer in medical aesthetics devices and injectables, competing head-to-head with DAXXIFY, RHA, and SkinPen.
- Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), a competing neurotoxin to DAXXIFY and Botox. It is a focused, pure-play aesthetics peer with a similar commercial strategy of targeting younger patients and switching from entrenched incumbents—making it a relevant direct comp on the neurotoxin side.
- Obagi Medical: Obagi is a medical-grade skincare company offering physician-dispensed products for anti-aging, hyperpigmentation, and acne. It competes directly with StriVectin, BIOJUVE, and the prescription/therapeutic skincare lines. It was also PE-owned (Valeant/BMGC) and serves as a useful comparable for exit dynamics.
- Revision Skincare: Revision Skincare is a physician-dispensed premium skincare brand focused on anti-aging and skin health, sold through medical practices. It directly competes with StriVectin in the professional channel and shares the same physician sales force motion.
- EltaMD: EltaMD is a leading mineral and broad-spectrum sunscreen brand widely used and recommended by dermatologists, directly competing with Blue Lizard Australian Sunscreen. Now owned by Colgate-Palmolive, it serves as both a competitive benchmark and an analog for consumer dermatology brand exit multiples.
Broad incumbents
- AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division houses Botox, Juvéderm, CoolSculpting, Latisse, and SkinMedica. It is the dominant incumbent in neurotoxins and hyaluronic acid fillers against which DAXXIFY and the RHA Collection directly compete, and SkinMedica competes in medical-grade skincare alongside StriVectin.
- SkinMedica (Allergan): SkinMedica is Allergan Aesthetics' physician-dispensed skincare line, including the TNS growth factor platform. It competes with StriVectin and BIOJUVE in the medical-grade skincare category, and is part of a much larger incumbent (AbbVie/Allergan) that bundles it with Botox/Juvéderm practices.
- CeraVe (L'Oréal): CeraVe, owned by L'Oréal, is the #1 dermatologist-recommended skincare brand in the US and competes in mass and prestige channels with StriVectin, PanOxyl, and other consumer brands. It represents the scale competitive threat in consumer dermatology that Crown/Revance's brands must navigate.
Emerging players
- Hugel America (Botulax/Letybo): Hugel is a South Korean biopharmaceutical company with the Letybo/Botulax neurotoxin (FDA-approved in the US in 2024). As another emerging neurotoxin entrant alongside DAXXIFY and Jeuveau, it represents competitive pressure on DAXXIFY's positioning against Botox in the US market.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Crown Laboratories social profiles
Digital presenceCrown Laboratories compliance and trust
Trust signalCompliance4 records
Crown Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Crown Laboratories leadership team
Management profileNumber of profiles
Profiles13 records
Crown Laboratories subsidiaries and ownership
Company hierarchySubsidiaries15 records
Crown Laboratories funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Crown Laboratories M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Crown Laboratories
What does Crown Laboratories do?
Crown Laboratories is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes aesthetics medical devices, neuromodulator injectables, dermal fillers, prescription dermatology products, and consumer skincare brands. The company sells aesthetics products (SkinPen, DAXXIFY, ProGen PRP, Teoxane RHA fillers) directly to medical practices while distributing consumer skincare brands (StriVectin, PanOxyl, Blue Lizard, BIOJUVE, Sarna, Keri) through retail, e-commerce, and direct-to-consumer channels across 60 countries.
Is Crown Laboratories a public or private company?
Crown Laboratories is a private company. It is classified as private equity controlled and is currently operating.
When was Crown Laboratories founded?
Crown Laboratories was founded in 2000. It employs 251 to 500 people.
Where is Crown Laboratories based?
Crown Laboratories is headquartered in Johnson City, United States, in the North America region.
How does Crown Laboratories make money?
Four revenue lines are on record. Aesthetics Products are the primary driver. The others are consumer Skincare Products, prescription and Therapeutic Products and contract Development and Manufacturing Services.
Who are Crown Laboratories's main competitors?
Direct peers on record are Galderma, Merz Aesthetics, Evolus, Obagi Medical, Revision Skincare and EltaMD. Broad incumbents are AbbVie (Allergan Aesthetics), SkinMedica (Allergan) and CeraVe (L'Oréal). Hugel America (Botulax/Letybo) is listed as an emerging player.
Does Crown Laboratories have an API?
No public API is recorded for Crown Laboratories.
What industry is Crown Laboratories in?
Crown Laboratories's product category is Dermatology and Aesthetics Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 42421 and its SIC code is 2834.